AllianceBernstein’s Matinas BioPharma MTNB Stock Holding History

AllianceBernstein’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-284	Closed	-$11K	–	3131
2018 Q1	$11K	Hold	284	–	–	﹤0.01%	3018
2017 Q4	$16K	Sell	284 -44	-13%	-$2.83K	﹤0.01%	3020
2017 Q3	$22K	Hold	328	–	–	﹤0.01%	3091
2017 Q2	$28K	Buy	+328	New	+$44K	﹤0.01%	3135

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

AllianceBernstein's MTNB Position: Q2 2018 in Review

AllianceBernstein sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 284 shares — an estimated $11K sold.

AllianceBernstein first reported a position in MTNB in Q2 2017 and held it in 4 quarters. The position peaked at $28K in Q2 2017. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

AllianceBernstein reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
AllianceBernstein sold 284 Matinas BioPharma shares in Q2 2018, an estimated $11K.
AllianceBernstein first reported a position in Matinas BioPharma in Q2 2017 and held it in 4 quarters.
AllianceBernstein's Matinas BioPharma position peaked at $28K in Q2 2017.
39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on AllianceBernstein's 13F filing for Q2 2018, filed 13 Aug 2018.